LAUSR

Vol. 30, No. 2, 2018 249 Received December 12, 2016, Revised April 10, 2017, Accepted for publication May 6, 2017 Corresponding author: Mu-Hyoung Lee, Department of Dermatology, Kyung Hee University Medical Center, 23 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Korea. Tel: 82-2-958-8512, Fax: 82-2-969-6538, E-mail: [email protected] This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Copyright © The Korean Dermatological Association and The Korean Society for Investigative Dermatology Hilari-Carbonell H, et al. Folliculocystic and collagen hamartoma of tuberous sclerosis complex. J Am Acad Dermatol 2012;66:617-621. 3. Nathan N, Wang JA, Li S, Cowen EW, Haughey M, Moss J, et al. Improvement of tuberous sclerosis complex (TSC) skin tumors during long-term treatment with oral sirolimus. J Am Acad Dermatol 2015;73:802-808. 4. Karar J, Maity A. PI3K/AKT/mTOR pathway in angiogenesis. Front Mol Neurosci 2011;4:51. 5. Zolli C, Rodrigues MM, Shannon GM. Unusual eyelid involvement in tuberous sclerosis. J Pediatr Ophthalmol 1976;13:156-158.